Teresa M. Petrella

Pertuzumab Monotherapy After Trastuzumab-Based Treatment and Subsequent Reintroduction of Trastuzumab: Activity and Tolerability in Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

Javier Cortés, P. Fumoleau, Giulia Bianchi et al. · Journal of Clinical Oncology · 2012 · 246 citations · Full text

Medicine, Oncology, Pharmacology +17

Interleukin-21 Has Activity in Patients With Metastatic Melanoma: A Phase II Study

Teresa M. Petrella, Richard Tozer, Karl Bélanger et al. · Journal of Clinical Oncology · 2012 · 124 citations · Full text

Medicine, Oncology, Pharmacology +17

Chemotherapy-induced nausea and vomiting in breast cancer patients: a prospective observational study.

Christopher M. Booth, Mark Clemons, George Dranitsaris et al. · PubMed · 2007 · 102 citations

Medicine, Oncology, Pharmacotherapy +13

Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study

Georgina V. Long, M.S. Carlino, Catriona M. McNeil et al. · Annals of Oncology · 2024 · 96 citations · Full text

Medicine, Dermatology, Oncology +17

4-year survival and outcomes after cessation of pembrolizumab (pembro) after 2-years in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in KEYNOTE-006.

Georgina V. Long, Jacob Schachter, Antoni Ribas et al. · Journal of Clinical Oncology · 2018 · 88 citations · Full text

Medicine, Oncology, Pharmacotherapy +17